Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Darrin Beaupre"'
Autor:
Timothy A. Yap, Ira Jacobs, Elodie Baumfeld Andre, Lauren J. Lee, Darrin Beaupre, Laurent Azoulay
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Randomized controlled trials (RCTs) that assess overall survival are considered the “gold standard” when evaluating the efficacy and safety of a new oncology intervention. However, single-arm trials that use surrogate endpoints (e.g., objective r
Externí odkaz:
https://doaj.org/article/c0a4a1ac7a1d4799ae548861fb16cf51
Autor:
Jordan Berlin, Darrin Beaupre, Robert A. Beckman, Abdel-Baset Halim, Agnes Ang, Chi-Yuan Wu, Thore Hettmann, Catherine Copigneaux, Lorrin Yee, Vicki Keedy, Lisa Malburg, Naiyer Rizvi, Moacyr Oliveira, Pasi A. Jänne, Patricia LoRusso
PDF - 278K, Supplementary Methods and Materials, QTc prolongation results. Supplementary Figure 1 - QTc prolongation compared with serum U3-1287 concentration. Supplementary Figure 2 - U3-1287-mediated pancreatic xenograft growth inhibition)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8088012567f918b89bc000dffe8b6149
https://doi.org/10.1158/1078-0432.22451111
https://doi.org/10.1158/1078-0432.22451111
Autor:
Jordan Berlin, Darrin Beaupre, Robert A. Beckman, Abdel-Baset Halim, Agnes Ang, Chi-Yuan Wu, Thore Hettmann, Catherine Copigneaux, Lorrin Yee, Vicki Keedy, Lisa Malburg, Naiyer Rizvi, Moacyr Oliveira, Pasi A. Jänne, Patricia LoRusso
Purpose: HER3 is a key dimerization partner for other HER family members, and its expression is associated with poor prognosis. This first-in-human study of U3-1287 (NCT00730470), a fully human anti-HER3 monoclonal antibody, evaluated its safety, tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50cdcfb073e4b7eaee807ce3fdcab11e
https://doi.org/10.1158/1078-0432.c.6522104.v1
https://doi.org/10.1158/1078-0432.c.6522104.v1
Publikováno v:
Cancer chemotherapy and pharmacology. 87(1)
The ideal starting dose for an oncology first-in-patient (FIP) trial should be low enough to be safe but not too far removed from therapeutically relevant doses. A low starting dose combined with small dose increments could lead to a lengthy dose esc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::97d117a2f7a8e7b7975b7a4d7ec97f70
https://pubmed.ncbi.nlm.nih.gov/33237334
https://pubmed.ncbi.nlm.nih.gov/33237334
Autor:
Hsu-Ping, Kuo, Scott A, Ezell, Sidney, Hsieh, Karl J, Schweighofer, Leo Wk, Cheung, Shiquan, Wu, Mutiah, Apatira, Mint, Sirisawad, Karl, Eckert, Yu, Liang, Jeff, Hsu, Chun-Te, Chen, Darrin, Beaupre, Betty Y, Chang
Publikováno v:
American journal of cancer research. 6(11)
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma and the most common subtype of non-Hodgkin lymphoma, accounting for roughly 30% of newly diagnosed cases in the United States. DLBCL can be separated into the activated B cell-like (AB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2431887dee95e294c159dfc53bf28a1d
https://pubmed.ncbi.nlm.nih.gov/27904766
https://pubmed.ncbi.nlm.nih.gov/27904766